Wugen
Kevin Li was a partner at HBM BioMed China from January 2007 to December 2010. Kevin is currently the director at Wugen.
Kevin Li earned a PhD in immunology from Indiana University Bloomington and did their postdoctoral research in the field of immunology at Stanford University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Wugen
Wugen is a clinical stage immuno-oncology cell therapy company, developing off-the-shelf NK and CAR-T cell therapies for the treatment of both solid tumor and heme malignancies.